MARKET

AGEN

AGEN

Agenus
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.680
-0.060
-2.19%
After Hours: 2.660 -0.02 -0.75% 19:53 01/21 EST
OPEN
2.740
PREV CLOSE
2.740
HIGH
2.810
LOW
2.680
VOLUME
4.03M
TURNOVER
--
52 WEEK HIGH
6.79
52 WEEK LOW
2.500
MARKET CAP
688.31M
P/E (TTM)
-23.5501
1D
5D
1M
3M
1Y
5Y
Do Options Traders Know Something About Agenus (AGEN) Stock We Don't?
Investors need to pay close attention to Agenus (AGEN) stock based on the movements in the options market lately.
Zacks · 01/10 13:38
Investors in Agenus (NASDAQ:AGEN) have made a decent return of 50% over the past three years
The last three months have been tough on Agenus Inc. ( NASDAQ:AGEN ) shareholders, who have seen the share price...
Simply Wall St. · 12/27/2021 09:11
Rtw Investments, Lp Buys Thermo Fisher Scientific Inc, Penumbra Inc, Tenaya Therapeutics Inc, ...
Investment company Rtw Investments, Lp (Current Portfolio) buys Thermo Fisher Scientific Inc, Penumbra Inc, Tenaya Therapeutics Inc, argenx SE, Macrogenics Inc, sells Quidel Corp, Protagonist Therapeutics Inc, MiMedx Group Inc, , Castle Biosciences Inc dur...
GuruFocus.com · 12/23/2021 17:38
Agenus Reports Balstilimab Plus Zalifrelimab Data Published In 'Journal Of Clinical Oncology': 'Objective response rate (ORR) of 32.8%'
Objective response rate (ORR) of 32.8% in PD-L1-positive patients and 25.6% in all patients regardless of PD-L1 status Both ORRs and durability of responses are higher than what has been demonstrated with approved
Benzinga · 12/22/2021 13:35
BRIEF-Agenus Inc Says Balstilimab Plus Zalifrelimab Data Published In Journal Of Clinical Oncology (JCO)
reuters.com · 12/22/2021 13:35
Boxer Capital, Llc Buys Tyra Biosciences Inc, Tango Therapeutics Inc, Blueprint Medicines Corp, ...
Investment company Boxer Capital, Llc (Current Portfolio) buys Tyra Biosciences Inc, Tango Therapeutics Inc, Blueprint Medicines Corp, Fulcrum Therapeutics Inc, Turning Point Therapeutics Inc, sells Seagen Inc, Amarin Corp PLC, Therapeutics Acquisition Cor...
GuruFocus.com · 12/21/2021 23:38
AGEN, LYG and ARVL among pre market gainers
Calliditas Therapeutics CALT +38% on FDA approval for kidney disease therapy. Kaixin Auto KXIN +27% on a partnership agreement with Bujia for 10k new energy trucks. Biomerica (NASDAQ:BMRA) +18% preliminary second quarter revenue increase of
Seekingalpha · 12/16/2021 13:44
HC Wainwright & Co. Initiates Coverage On Agenus with Buy Rating, Announces Price Target of $12
HC Wainwright & Co. analyst Michael King initiates coverage on Agenus (NASDAQ:AGEN) with a Buy rating and announces Price Target of $12.
Benzinga · 12/16/2021 11:19
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AGEN. Analyze the recent business situations of Agenus through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
25.00%Buy
25.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average AGEN stock price target is 10.00 with a high estimate of 12.00 and a low estimate of 7.00.
High12.00
Average10.00
Low7.00
Current 2.680
EPS
Actual
Estimate
-0.120.140.390.65
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 215
Institutional Holdings: 122.46M
% Owned: 47.68%
Shares Outstanding: 256.83M
TypeInstitutionsShares
Increased
64
16.03M
New
43
3.64M
Decreased
32
4.96M
Sold Out
19
9.48M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.82%
Pharmaceuticals & Medical Research
-1.11%
Key Executives
Chairman/Chief Executive Officer/Co-Founder/Director
Garo Armen
Chief Compliance Officer/Vice President/General Counsel/Secretary
Evan Kearns
Vice President - Finance
Christine Klaskin
Other
Steven Oday
Lead Director/Independent Director
Timothy Wright
Independent Director
Brian Corvese
Independent Director
Susan Hirsch
Independent Director
Allison Jeynes-Ellis
Independent Director
Wadih Jordan
Independent Director
Ulf Wiinberg
No Data
About AGEN
Agenus Inc. (Agenus) is a clinical-stage immuno-oncology (I-O) company. It has a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer. Its I-O assets include antibody-based therapeutics, monospecific and bispecific antibodies, cell therapy, neoantigen cancer vaccines (individualized and off-the shelf) platforms and adjuvants. Its anti-PD-1 antibody and first-generation and next generation anti-CTLA-4 antagonists are in clinical development. Its pipeline of pre-clinical assets, which include AGEN1777, an anti-TIGIT bispecific antibody and AGEN1327, an anti-TIGIT monospecific antibody. Its neoantigen vaccine platforms include its heat shock protein (HSP) based Prophage vaccine candidates and its synthetic, neoantigen vaccine candidates, AutoSynVax (ASV) and PhosphoSynVax (PSV). Its neoantigen vaccine platforms include individualized ASV and off-the-shelf PSV, which target antigens expressed across patients and tumors.

Webull offers kinds of Agenus Inc stock information, including NASDAQ:AGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AGEN stock methods without spending real money on the virtual paper trading platform.